

BMJ

www.bmj.com

BMJ 326:357 doi:10.1136/bmj.326.7385.357 (Published 15 February 2003)

Paper

Commentary: [matched cohorts can be useful](#)

## Short and long term mortality associated with foodborne bacterial gastrointestinal infections: registry based study

Morten Helms, research fellow<sup>a</sup>, Pernille Vastrup, statistician<sup>a</sup>, Peter Gerner-Smidt, consultant<sup>b</sup>, Kåre Mølbak ([krm@ssi.dk](mailto:krm@ssi.dk)), staff specialist<sup>b</sup>

+ Author Affiliations

Correspondence to: K Mølbak

Accepted 5 November 2002

### Abstract

**Objectives:** To determine the excess mortality associated with infections with *Salmonella*, *Campylobacter*, *Yersinia enterocolitica*, and *Shigella* and to examine the effect of pre-existing illness.

**Design:** Registry based, matched cohort study.

**Setting:** Denmark.

**Participants:** 48 857 people with gastrointestinal infections plus 487 138 controls from the general population.

**Main outcome measure:** One year mortality among patients with gastrointestinal infections compared with controls after adjustment for comorbidity.

**Results:** 1071 (2.2%) people with gastrointestinal infections died within one year after infection compared with 3636 (0.7%) controls. The relative mortality within one year was 3.1 times higher in patients than in controls. The relative mortality within 30 days of infection was high in all four bacterial groups. Furthermore, there was excess mortality one to six months after infection with *Yersinia enterocolitica* (relative risk 2.53, 95% confidence interval 1.38 to 4.62) and from six months to one year after infection with *Campylobacter* (1.35, 1.02 to 1.80) and *Salmonella* (1.53, 1.31 to 1.79).

**Conclusions:** Infections with all these bacteria were associated with an increased short term risk of death, even after pre-existing illnesses were taken into account. *Salmonella*, *Campylobacter*, and *Yersinia enterocolitica* infections were also associated with increased long term mortality.

### What is already known on this topic

Foodborne bacterial infections have a major effect on the public health and economy of industrialised countries

Most estimates of mortality are short term and do not take into account coexisting illnesses

### What this study adds

Patients infected with *Salmonella*, *Campylobacter*, *Yersinia*, and *Shigella* had higher 30 day mortality than controls after comorbidity was taken into account

*Salmonella*, *Campylobacter*, and *Yersinia* infections were also associated with increased long term mortality

## Introduction

Foodborne bacterial infections have a major and perhaps increasing effect on the public health and economy of industrialised countries.<sup>1–4</sup> It is difficult to determine the exact mortality associated with bacterial infections that are usually foodborne. Pathogen specific surveillance systems rarely collect systematic information on outcomes of illness, and outcome specific surveillance systems (such as death certificates) greatly under-report many pathogen specific conditions.<sup>5</sup>

The quantification of the public health impact of bacterial foodborne infections is further complicated by their interaction with chronic underlying diseases and associated conditions.<sup>6–7</sup> We report new estimates of the excess mortality associated with infections with *Salmonella*, *Campylobacter*, *Yersinia enterocolitica*, and *Shigella* spp. By using data from Danish population based registries, we determined the long term effect on survival adjusted for coexisting illness.

## Methods

We obtained data for the study from the national registry of enteric pathogens, the Danish civil registration system, the national registry of patients, and the cancer registry. Bacterial foodborne infections are diagnosed at our institute and 10 local clinical microbiology laboratories. The institute is notified of positive findings and records them in the national registry of enteric pathogens. If a bacterial species or *Salmonella* serotype is found more than once from the same person within six months, only the first positive sample is registered.

We included all patients with culture confirmed infections with non-typhoidal *Salmonella*, *Campylobacter* spp, *Yersinia enterocolitica*, or *Shigella* spp registered between 1 January 1991 and 31 October 1999. To compare the mortality of patients with that of people without known bacterial gastrointestinal infections, we used data from the civil registration system, which assigns a personal identification number to all liveborn children and citizens of Denmark.<sup>8</sup> For every patient, we randomly selected 10 people matched for age, sex, and county of residence who were alive on the date the sample was received. We obtained information on vital status, date of death or emigration, and county of residence for patients and controls. Finally, we obtained data on all hospital discharges, outpatient attendances (since January 1995), and cancer diagnoses up to five years before entry in the study from the national registry of patients and the cancer registry. This allowed us to control for pre-existing illness (comorbidity).

## Statistical methods

We created a comorbidity index using the principles described by Charlson et al.<sup>9</sup> This index is a sum of weights corresponding to the number and severity of coexisting illnesses. We first calculated the relative mortality associated with different diagnostic groups, using data from the background population. These relative rates served as weights in the further survival analyses. We then created the index by adding log transformed weights, taking into account multiple discharges before entry into the study. We excluded diagnostic groups associated with a relative mortality less than 1.2. We forced this index into the survival analyses, so that any difference between the mortality of patients and the general population quantified mortality beyond that attributable to underlying illness.<sup>10–13</sup>

To compare the mortality of patients with that of the general population, we stratified the data so that each stratum contained one patient and 10 controls. We preserved the matching in all analyses by using conditional proportional hazard regression to control for age, sex, and county of residence. The analysis was conducted with SAS software (version 6.12), with proportional hazards regression procedure (PHREG).

## Results

During the study, 49 149 patients had bacterial gastrointestinal infections registered, 48 857 (99.4%) of whom could be linked to the civil registry system. Of these patients, 26 974 (55.2%) had *Salmonella* infection, 16 180 (33.1%) *Campylobacter* infection, 4045 (8.3%) *Yersinia* infection, and 1658 (3.4%) *Shigella* infection. A total of 1071 (2.2%) deaths were registered up to one year after infection compared with 3636 (0.7%) deaths among the 487 138 controls. Patients infected with one of the four enteric pathogens had a 3.1 times higher mortality than controls (95% confidence interval 2.89 to 3.33).

A total of 2645 patients had one or more of the diseases included in the comorbidity index. Table 1 shows the number of patients and the various diagnostic groups used in the index, the weights of the diagnostic groups, and the relative risk of belonging to one of the diagnostic groups compared with the reference group. Underlying conditions were more common among patients than in the control group, particularly AIDS related illness, metastatic cancers, and lymphomas or leukaemia. After we adjusted for comorbidity, the relative mortality fell from 3.10 to 2.56 (95 % confidence interval 2.38 to 2.76).

View this table: [In this window](#) [In a new window](#)

**Table 1**

Comorbidity in 48 857 patients with *Salmonella*, *Campylobacter*, *Shigella*, and *Yersinia* infections, Denmark, 1991-9

Table 2 summarises the cumulative mortality (Kaplan-Meier estimates) and relative mortality by time since infection. The relative mortality in the 30 days after the episode date ranged from 3.63 to 22.03 for the four bacteria. No excess mortality was seen after 30 days for *Shigella* and 180 days for *Yersinia enterocolitica*, but for *Salmonella* and *Campylobacter*, we found an excess mortality up to one year after infection.

View this table: [In this window](#) [In a new window](#)

**Table 2**

Mortality among 48 857 patients with *Salmonella*, *Campylobacter*, *Shigella*, and *Yersinia* infection compared with matched controls from the general population and adjusted for comorbidity, Denmark, 1991-9

Table 3 shows the relative mortality before and after we adjusted for coexisting illness. After adjusting for comorbidity, we found that mortality in patients infected with *Salmonella dublin* was more than 12 times higher than in the control group. For other *Salmonella* serotypes, *Campylobacter*, and *Yersinia enterocolitica* mortality was 1.86 to 2.88 times higher than in the control group. Infection with *Shigella* species was not associated with higher mortality after we adjusted for comorbidity.

View this table: [In this window](#) [In a new window](#)

### Table 3

Crude and adjusted relative mortality within one year in 48 857 patients with *Salmonella*, *Campylobacter*, *Yersinia*, and *Shigella* infection compared with control group matched for age, sex, and county of residence, Denmark 1991-9

In all, 288 (0.6%) patients were admitted to hospital within 30 days of infection with a diagnosis of an invasive illness (septicaemia, endocarditis, aneurysm, meningitis, pneumonia, abscesses, pancreatitis, or hepatitis). In the control group, 44 (<0.01%) were admitted. The relative mortality among patients with an invasive illness within one year was 17.46 (95% confidence interval 10.11 to 30.17). Among patients with no known invasive illness, the relative mortality was 2.47 times higher than in the control group (2.29 to 2.67).

Of the 48 857 patients with gastrointestinal infection, 46 212 (94.6%) had no other illness included in the comorbidity index. The corresponding figure for the control group was 472 924 (97.1%). Table 4 shows the relative mortality of this group of patients compared with the control group.

View this table: [In this window](#) [In a new window](#)

### Table 4

Relative mortality within one year in 46 212 patients without any known coexisting disease compared with controls

## Discussion

Most foodborne gastrointestinal infections are self limiting. However, in a subset of patients they can cause severe complications and increased risk of death. Few large systematic studies exist of mortality from foodborne diseases, and the generalisability of the evidence from case reports and outbreaks is questionable. The most recent estimates of mortality were obtained by calculating death rates from the US FoodNet surveillance.<sup>5</sup> The authors assumed that deaths attributable to the foodborne infections were limited to the acute phase of infection and the confounding effect of comorbidity was not taken into account. We were able to examine long term mortality and control for coexisting illness in a large, unselected group of patients. As we used registries created for other purposes, the data should be unbiased.

### Effect on mortality

Overall, patients had a 3.10 times higher mortality than the background population within one year of follow up. This figure reflects both acute and long term consequences of foodborne illness as well as the effect of underlying diseases, and it conceals large differences between the bacterial types.

The acute relative mortality was high for all four bacteria after we adjusted for comorbidity (22 for *Shigella*, 13 for *Salmonella*, 5 for *Campylobacter* and 4 for *Yersinia enterocolitica*; table 2). The difference in 30 day cumulative mortality between patients and controls, which correlates to the case fatality rate reported by others, was 1.15% for *Salmonella*, 0.23% for *Campylobacter*, 0.14% for *Yersinia enterocolitica*, and 0.29% for *Shigella*. These figures are in line with the FoodNet case fatality rate for *Yersinia enterocolitica* (0.14%) but are higher than the rates reported for *Salmonella* (0.78%), *Campylobacter* (0.10%) and *Shigella* (0.05%).<sup>5</sup>

We found significant excess long term mortality up to one year after infection with zoonotic *Salmonella* serotypes and *Campylobacter* and up to six months after *Yersinia enterocolitica* infections. By contrast, *Shigella* was mainly associated with death in the acute phase. Unfortunately, valid information on causes of deaths was not available.

### Comorbidity

After we adjusted for imbalances in comorbidity, patients infected with *Salmonella*, *Campylobacter*, or *Yersinia enterocolitica* continued to have a higher mortality than the control group, although the differences were smaller. The high mortality associated with *Salmonella dublin* infections probably reflects its more invasive character.<sup>14–16</sup>

Our comorbidity index is based on discharge diagnoses and on data from outpatient clinics but did not include data from general practitioners. It could be argued that this weakens the index. However, any patient with a pre-existing disease severe enough to alter the outcome of a foodborne infection is likely to have come into contact with a hospital or an outpatient clinic in the five years before infection. Nevertheless, people with other illnesses may have increased mortality and an independent excess risk of gastrointestinal infection. These people may also be more likely to seek medical attention and have a sample specimen taken than patients without known comorbidity. Among these people, the diagnosis of a gastrointestinal infection may be a marker of excess mortality rather than a contributing cause. However, only a small proportion of patients had a coexistent illness, and the excess mortality was similar in patients with and without underlying illness. Furthermore, there was an excess mortality independent of invasive illness.

### Causes of long term mortality

The late excess mortality may have several explanations, including infectious and reactive complications or sequelae, relapses of the initial infection, and reduced efficacy or treatment failure in the case of antimicrobial drug resistance. Complications and sequelae may occur weeks to months after the initial infection and include sequelae of invasive illness (septicaemia, endocarditis, vasculitis, septic arthritis, etc), intestinal perforation, abscesses, and complications of surgery.

The registry did not include multiple diagnoses of the same bacterial species or serotype. We therefore could not examine the importance of relapses. We had only limited data on antimicrobial drug resistance and no information about treatment with antimicrobial drugs and were not able to study this issue. Studies from the United States suggest that treatment with antimicrobials is a risk factor for infection with drug resistant bacteria, and that this interaction may contribute to mortality.<sup>17 18</sup> We have previously shown that quinolone resistance may be associated with excess mortality.<sup>19</sup>

## Conclusions

The four foodborne bacterial species we examined were all associated with increased acute mortality. In addition, *Salmonella*, *Campylobacter*, and *Yersinia enterocolitica* were associated with increased long term mortality. Our data suggest that current estimates of the burden of foodborne diseases underestimate the number of deaths from bacterial gastrointestinal infections.

## Acknowledgments

We thank Per Krag Andersen for statistical advice.

Contributors: MH assembled and analysed the data and drafted the article. PV did the statistical analysis and critically revised the article. PG-S was responsible for the registry of enteric pathogens and critically revised the article. KM was responsible for the concept and design of the study, critically revised the article, and is the guarantor. All authors contributed to writing the final manuscript.

## Footnotes

**Funding** The Research Centre for Environmental Health (Danish Ministry of Health) and the Danish Directorate for Food, Fisheries, and Agro Business (Ministry of Food, Agriculture and Fisheries).

**Competing interests** None declared.

## References

1. Todd EC. Epidemiology of foodborne diseases: a worldwide review. *World Health Stat Q* 1997;50:30–50. [\[Find it McGill\]](#) [\[Medline\]](#)
2. De Wit MA, Hoogenboom-Verdegaal AM, Goosen ES, Sprenger MJ, Borgdorff MW. A population-based longitudinal study on the incidence and disease burden of gastroenteritis and Campylobacter and Salmonella infection in four regions of the Netherlands. *Eur J Epidemiol* 2000;16:713–718. [\[Find it McGill\]](#) [\[CrossRef\]](#) [\[Medline\]](#) [\[Web of Science\]](#)
3. Potter ME, Tauxe RV. Epidemiology of foodborne diseases: tools and applications. *World Health Stat Q* 1997;50:24–29. [\[Find it McGill\]](#) [\[Medline\]](#)
4. Altekruse SF, Cohen ML, Swerdlow DL. Emerging foodborne diseases. *Emerg Infect Dis* 1997;3:285–293. [\[Find it McGill\]](#) [\[Medline\]](#) [\[Web of Science\]](#)
5. Mead PS, Slutsker L, Dietz V, McCaig LF, Bresee JS, Shapiro C, *et al.* Food-related illness and death in the United States. *Emerg Infect Dis* 1999;5:607–625. [\[Find it McGill\]](#) [\[Medline\]](#) [\[Web of Science\]](#)
6. Mauskopf JA, French MT. Estimating the value of avoiding morbidity and mortality from foodborne illnesses. *Risk Anal* 1991;11:619–631. [\[Find it McGill\]](#) [\[CrossRef\]](#) [\[Medline\]](#) [\[Web of Science\]](#)
7. Banatvala N, Cramp A, Jones IR, Feldman RA. Salmonellosis in North Thames (East), UK: associated risk factors. *Epidemiol Infect* 1999;122:201–207. [\[Find it McGill\]](#) [\[CrossRef\]](#) [\[Medline\]](#)
8. Mosbech J, Jorgensen J, Madsen M, Rostgaard K, Thornberg K, Poulsen TD. [The national patient registry. Evaluation of data quality (in Danish).] *Ugeskr Laeger* 1995;157:3741–3745. [\[Find it McGill\]](#) [\[Medline\]](#)
9. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis* 1987;40:373–383. [\[Find it McGill\]](#) [\[CrossRef\]](#) [\[Medline\]](#) [\[Web of Science\]](#)
10. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. *Med Care* 1998;36:8–27. [\[Find it McGill\]](#) [\[CrossRef\]](#) [\[Medline\]](#) [\[Web of Science\]](#)
11. Cleves MA, Sanchez N, Draheim M. Evaluation of two competing methods for calculating Charlson's comorbidity index when analysing short-term mortality using administrative data. *J Clin Epidemiol* 1997;50:903–908. [\[Find it McGill\]](#) [\[CrossRef\]](#) [\[Medline\]](#) [\[Web of Science\]](#)
12. D'Hoore W, Sicotte C, Tilquin C. Risk adjustment in outcome assessment: the Charlson comorbidity index. *Methods Inf Med* 1993;32:382–387. [\[Find it McGill\]](#) [\[Medline\]](#) [\[Web of Science\]](#)
13. D'Hoore W, Bouckaert A, Tilquin C. Practical considerations on the use of the Charlson comorbidity index with administrative data bases. *J Clin Epidemiol* 1996;49:1429–1433. [\[Find it McGill\]](#) [\[CrossRef\]](#) [\[Medline\]](#) [\[Web of Science\]](#)
14. Lester A, Bruun BG, Husum P, Kolmos HJ, Nielsen BB, Scheibel JH, *et al.* [Salmonella Dublin.] *Ugeskr Laeger* 1995;157:20–24. [\[Find it McGill\]](#) [\[Medline\]](#)
15. Lester A, Eriksen NH, Nielsen H, Nielsen PB, Friis-Møller A, Bruun BG, *et al.* [Bacteremia caused by zoonotic Salmonella types in greater Copenhagen in 1984–1988.] *Ugeskr Laeger* 1990;152:529–532. [\[Find it McGill\]](#) [\[Medline\]](#)
16. Fang FC, Fierer J. Human infection with Salmonella Dublin. *Medicine (Baltimore)* 1991;70:198–207. [\[Find it McGill\]](#) [\[Medline\]](#)
17. Cohen ML, Tauxe RV. Drug-resistant Salmonella in the United States: an epidemiologic perspective. *Science* 1986;234:964–969. [\[Abstract/FREE Full text\]](#)
18. Ryan CA, Nickels MK, Hargrett-Bean NT, Potter ME, Endo T, Mayer L, *et al.* Massive outbreak of antimicrobial-resistant salmonellosis traced to pasteurized milk. *JAMA* 1987;258:3269–3274. [\[Abstract/FREE Full text\]](#)
19. Helms M, Vastrup P, Gerner-Smidt P, Mølbak K. Excess mortality associated with antimicrobial drug-resistant, particularly quinolone-resistant, Salmonella typhimurium. *Emerg Infect Dis* 2002;8:490–495. [\[Find it McGill\]](#) [\[Medline\]](#) [\[Web of Science\]](#)

## Commentary: matched cohorts can be useful

**Stephen Evans** ([Stephen.Evans@shhtm.ac.uk](mailto:Stephen.Evans@shhtm.ac.uk)), professor of pharmacoepidemiology

### Author Affiliations

Most *BMJ* readers are familiar with matched case-control studies but fewer will be familiar with matched cohort studies. Case-control studies are based on selecting cases of a disease and then finding people who are as similar as possible to the cases. The study by Helms *et al* is not a case-control study; people were selected not on the basis of having, or not having, the outcome of interest (in this instance mortality) but on the basis of being exposed or not to something that may affect mortality.

Matched cohort studies have been published in the *BMJ* before—for example, a study examining air bags and deaths of car drivers.<sup>1</sup> Helms *et al* have used similar methods with Danish national data to look at *Salmonella* (reference 19 of their paper). A common feature of these studies is the existence of a large database in which the individuals who are exposed (to bacterial infection or air bags) can be compared with similar unexposed people. Helms *et al* used record linkage between databases, obtaining data from microbiology laboratories to define exposed patients and using the national Danish civil registration system to obtain unexposed people from the general population. They also used the registration system to obtain outcome data on subsequent mortality for exposed and unexposed people and two further databases to determine possible confounding from hospital admissions for diseases other than bacterial infection.

The main method of analysis for cohort studies is to use the time taken to an event that is the outcome under study, a survival analysis. The outcome is usually death, but it could be another event such as diagnosis of myocardial infarction or cancer. Cohort studies usually have to be very large to obtain a sufficient number of outcome events. This may make their costs prohibitive, but with electronic databases the costs can be greatly reduced. Similarly, the costs of carrying out matching in cohort studies have restricted their use. Matching prevents the possible association between the matching factors and the exposure at the start of the study, although not necessarily associations occurring as an observational study progresses. Matching should be taken into account in the (conditional) analysis, as has been done by Helms *et al*.<sup>2</sup>

Matching may not increase statistical power (efficiency) but it does not introduce bias (as it does in case-control studies).<sup>3</sup> With large databases any small loss in efficiency may

be unimportant, and the convincing power to the reader of the similarity of the exposed and unexposed cohorts at the start is a gain.

What factors should be used for matching? Helms et al used age, sex, and county of residence. They have used a 1:10 exposed:unexposed ratio. They have also adjusted the survival analysis for comorbidity, based on eight different diagnostic groups. It is possible to match for morbidity or other risk factors, but it would make matching difficult and may not offer any gains. An alternative, used particularly in drug safety, is to match on a "propensity" score.<sup>4</sup> This score measures the likelihood of being given the treatment rather than the likelihood of having the outcome. The purpose is to reduce confounding in either the design or the analysis so that comparisons are valid.

Scandinavia has better national databases than elsewhere, but the United Kingdom has good databases based on general practitioners' computer records. The potential of these is considerable, and matched cohort designs could be used more often. Concerns over confidentiality of records may make this difficult, but it is to be hoped that good epidemiology is not going to be stopped because of misguided ethicists and lawyers.<sup>5</sup>

## Footnotes

**Competing interests** None declared.

## References

1. Cummings P, McKnight B, Rivara FP, Grossman DC. Association of driver air bags with driver fatality: a matched cohort study. *BMJ* 2002;324:1119–1122. [\[Abstract/FREE Full text\]](#)
2. Rothman KJ, Greenland S. *Modern epidemiology*. 2nd ed. Philadelphia: Lippincott-Raven, 1998.
3. Greenland S, Morgenstern H. Matching and efficiency in cohort studies. *Am J Epidemiol* 1990;131:151–159. [\[Abstract/FREE Full text\]](#)
4. Wang J, Donnan PT. Propensity score methods in drug safety studies: practice, strengths, and limitations. *Pharmacoepidemiol Drug Saf* 2001;10:341–344. [\[Find it McGill\]](#)
5. Walton J, Doll R, Asscher W, Hurley R, Langman M, Gillon R, et al. Consequences for research if use of anonymised patient data breaches confidentiality. *BMJ* 1999;319:1366. [\[FREE Full text\]](#)

## Relevant Articles:

### This Week In the BMJ:

#### Stomach bugs kill more than estimated

*BMJ* 2003;326:doi:10.1136/bmj.326.7385.0 (Published 15 February 2003)

[\[Full text\]](#)

## Rapid responses to this article

### Re: Over estimation of mortality rates in cases with foodborne bacterial infections

Kåre Mølbak, Morten Helms, Peter Gerner-Smidt

*BMJ* 28 March 2003

[\[Full text\]](#)

### Over estimation of mortality rates in cases with foodborne bacterial infections

Phillippa M Cumberland, Jenny Roberts and Laura Rodrigues

*BMJ* 18 March 2003

[\[Full text\]](#)

### Re: About case selection and clinical data

Kåre Mølbak, Morten Helms, Peter Gerner-Smidt

*BMJ* 12 March 2003

[\[Full text\]](#)

### About case selection and clinical data

Sarah J. O'Brien, Roger A. Feldman

*BMJ* 7 March 2003

[\[Full text\]](#)

### Re: matched cohorts can be useful

Darren C Greenwood

*BMJ* 4 March 2003

[\[Full text\]](#)

### Reply to Lewis A. Cox and Adam Jacobs

Kåre Mølbak, Morten Helms and Pernille Vastrup

*BMJ* 21 February 2003

[\[Full text\]](#)

### Mortality associated with foodborne bacterial gastrointestinal infections reexamined

Louis A. Cox

*BMJ* 19 February 2003

[\[Full text\]](#)

### Was the result specific to gastrointestinal infections?

Adam Jacobs

*BMJ* 18 February 2003

[\[Full text\]](#)

### Should the system of death certification be changed?

Arpan Dutta

*BMJ* 17 February 2003

[\[Full text\]](#)

## Relevant Articles

#### Letter:

#### Mortality associated with foodborne bacterial gastrointestinal infections : Mechanism needs to be explained

Philip P Mortimer

*BMJ* 2003;326:1265 doi:10.1136/bmj.326.7401.1265-b (Published 5 June 2003)

[\[Extract\]](#) [\[Full text\]](#)

#### Letter:

#### Mortality associated with foodborne bacterial gastrointestinal infections : Statistical method is worth examining

Louis Anthony Cox

*BMJ* 2003;326:1265 doi:10.1136/bmj.326.7401.1265 (Published 5 June 2003)

[\[Extract\]](#) [\[Full text\]](#) [\[PDF\]](#)

## This article has been cited by other articles:

#### Barriers to surge capacity of an overcrowded emergency department for a serious foodborne disease outbreak

*Emerg. Med. J.* 2010;27:779

[\[Abstract\]](#) [\[Full text\]](#) [\[PDF\]](#)

#### Cesarean Delivery and Risk of Intestinal Bacterial Infection

*The Journal of Infectious Disease* 2010;201:898

[\[Abstract\]](#) [\[Full text\]](#) [\[PDF\]](#)

#### Efficient sampling approaches to address confounding in database studies

*Stat Methods Med Res* 2009;18:81

[\[Abstract\]](#) [\[PDF\]](#)

#### Food animal-associated Salmonella challenges: Pathogenicity and antimicrobial resistance

*J ANIM SCI* 2008;86:E173

[\[Abstract\]](#) [\[Full text\]](#) [\[PDF\]](#)

#### A Meta-Analysis on the Effects of Antibiotic Treatment on Duration of Symptoms Caused by Infection with *Campylobacter* Species

*Clinical Infectious Diseases* 2007;44:696

[\[Abstract\]](#) [\[Full text\]](#) [\[PDF\]](#)

**One relative risk versus two odds ratios: implications for meta-analyses involving paired and unpaired binary data**

*Clin Trials* 2007;4:25

[\[Abstract\]](#) [\[PDF\]](#)

**Commentary: We still need observational studies of drugs--they just need to be better.**

*Int J Epidemiol* 2006;35:1310

[\[Full text\]](#) [\[PDF\]](#)

**Macrolide resistance in *Campylobacter jejuni* and *Campylobacter coli***

*J Antimicrob Chemother* 2006;58:243

[\[Abstract\]](#) [\[Full text\]](#) [\[PDF\]](#)

**Foodborne Bacterial Infection and Hospitalization: A Registry-Based Study**

*Clinical Infectious Diseases* 2006;42:498

[\[Abstract\]](#) [\[Full text\]](#) [\[PDF\]](#)

**Nontyphoidal *Salmonella* from Human Clinical Cases, Asymptomatic Children, and Raw Retail Meats in Yucatan, Mexico**

*Clinical Infectious Diseases* 2006;42:21

[\[Abstract\]](#) [\[Full text\]](#) [\[PDF\]](#)

**Genomic Diversity of *Campylobacter coli* and *Campylobacter jejuni* Isolates Recovered from Free-Range Broiler Farms and Comparison with Isolates of Various Origins**

*Appl. Environ. Microbiol.* 2005;71:6216

[\[Abstract\]](#) [\[Full text\]](#) [\[PDF\]](#)

**Prevalence of diarrhoea in the community in Australia, Canada, Ireland, and the United States**

*Int J Epidemiol* 2005;34:454

[\[Abstract\]](#) [\[Full text\]](#) [\[PDF\]](#)

**Adverse Health Events Associated with Antimicrobial Drug Resistance in *Campylobacter* Species: A Registry-Based Cohort Study**

*The Journal of Infectious Disease* 2005;191:1050

[\[Abstract\]](#) [\[Full text\]](#) [\[PDF\]](#)

**Molecular characterization of class 1 integrons from Irish thermophilic *Campylobacter* spp.**

*J Antimicrob Chemother* 2004;53:952

[\[Abstract\]](#) [\[Full text\]](#) [\[PDF\]](#)

**Genotypic and Antibiotic Susceptibility Characteristics of a *Campylobacter coli* Population Isolated from Dairy Farmland in the United Kingdom**

*Appl. Environ. Microbiol.* 2004;70:822

[\[Abstract\]](#) [\[Full text\]](#) [\[PDF\]](#)

**Turtle-Associated Human Salmonellosis**

*Clinical Infectious Diseases* 2003;37:e167

[\[Abstract\]](#) [\[Full text\]](#) [\[PDF\]](#)

**Clinical Review of Nontyphoid *Salmonella* Infections from 1991 to 1999 in a Danish Country**

*Clinical Infectious Diseases* 2003;37:e47

[\[Abstract\]](#) [\[Full text\]](#) [\[PDF\]](#)

**Gastrointestinal Infection Associated with Increased Mortality**

*JWatch Infect. Diseases* 2003;2003:11

[\[Full text\]](#)

**Foodborne Illness: Worse for Us Than We Thought**

What's new

- Last 7 days
- Past weeks
- Current print issue
- Rapid responses
- BMJ iPad app
- Article clusters

BMJ Group portals

- Cardiology
- Diabetes
- Oncology
- Psychiatry
- Junior doctors
- Clinical trials
- Neurology
- NHS reforms
- Respiratory medicine
- Stroke

Blogs

Podcasts

- [Domhnall MacAuley: Ghosts in the consulting room \(4 Nov 2011\)](#)
- [Martin McShane: A day at the Mid Staffordshire foundation trust enquiry \(4 Nov 2011\)](#)
- [Research highlights – 4 November 2011 \(4 Nov 2011\)](#)
- [Grania Brigden: Paediatric tuberculosis: out of the dark \(4 Nov 2011\)](#)
- [Desmond O'Neill: Quantitative easing – the academic version \(3 Nov 2011\)](#)

Keep updated

Get email alerts



Get RSS alerts



- Latest from BMJ
- BMJ simple search
- Follow BMJ on twitter
- Watch on YouTube

Services

- Submit an article
- Subscribe/Activate
- Request permissions

Tools

Print this page

Online poll

Do we need to curb population growth to achieve global health?

- No
- Yes

[View Results](#)

Find out more [here](#).

## Resources

[Readers](#)  
[Authors](#)  
[Reviewers](#)  
[Media](#)  
[BMA members](#)  
[Advertising and sponsors](#)  
[Subscribers](#)

## Print issues

[Current issue contents](#)  
[Current cover image](#)  
[Past issues](#)  
[Subscribe](#)

